Lapatinib ditosylate monohydrate (GW572016 ditosylate monohydrate) | ErbB-2/EGFR Inhibitor

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	388082-78-8
Formula :	C₄₃H₄₄ClFN₄O₁₁S₃
M.W :	943.48
SMILES Code :	O=S(CCNCC1=CC=C(C2=CC3=C(NC4=CC=C(OCC5=CC=CC(F)=C5)C(Cl)=C4)N=CN=C3C=C2)O1)(C)=O.O=S(C6=CC=C(C)C=C6)(O)=O.O=S(C7=CC=C(C)C=C7)(O)=O.[H]O[H]
Synonyms :	GW2016 ditosylate monohydrate; GW572016 ditosylate monohydrate; Lapatinib tosilate hydrate
MDL No. :	MFCD18904381

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

BT474 cells	1 μM	overnight	Lapatinib inhibited FASN phosphorylation.	PMC3046439
SKBR3 cells	1 μM	18 h	Lapatinib inhibited EGFR and HER2 phosphorylation and led to dephosphorylation of FASN.	PMC3046439
SKBR3 cells	10 nM	72 h	To evaluate the effects of dual HER2 blockade on HER2-E breast cancer cell lines, results showed that SKBR3 cell line did not switch to Luminal A phenotype after treatment.	PMC6971277
BT474 cells	10 nM	72 h	To evaluate the effects of dual HER2 blockade on HER2-E breast cancer cell lines, results showed that BT474 cell line switched to Luminal A phenotype after treatment.	PMC6971277
UACC893 cells	1 μM	72 h	To evaluate the antiproliferative effect of lapatinib on HER2-amplified breast cancer cells. Results showed that lapatinib inhibited HER2 phosphorylation, but the inhibition of PI3K signaling was attenuated in PIK3CA-mutant cells.	PMC3978602
HCC1954 cells	1 μM	72 h	To evaluate the antiproliferative effect of lapatinib on HER2-amplified breast cancer cells. Results showed that lapatinib inhibited HER2 phosphorylation, but the inhibition of PI3K signaling was attenuated in PIK3CA-mutant cells.	PMC3978602
MDA-MB-361 cells	1 μM	72 h	To evaluate the antiproliferative effect of lapatinib on HER2-amplified breast cancer cells. Results showed that lapatinib inhibited HER2 phosphorylation, but the inhibition of PI3K signaling was attenuated in PIK3CA-mutant cells.	PMC3978602
SKBR3 cells	1 μM	72 h	To evaluate the antiproliferative effect of lapatinib on HER2-amplified breast cancer cells. Results showed that lapatinib inhibited HER2 phosphorylation, but the inhibition of PI3K signaling was attenuated in PIK3CA-mutant cells.	PMC3978602
CD24HiCD49fHiLin− TIC-enriched cells	5 μM	10 min	Inhibition of Nrg1-mediated activation of Akt and Erk1/2	PMC3917843
BT474 cells	1 μM	72 h	To evaluate the antiproliferative effect of lapatinib on HER2-amplified breast cancer cells. Results showed that lapatinib inhibited HER2 phosphorylation, but the inhibition of PI3K signaling was attenuated in PIK3CA-mutant cells.	PMC3978602
NUGC-4 cell lines	69 nM(GI50)	3 days	Evaluate the anti-proliferative effect of Lapatinib on HER2-high gastric cancer cell lines, results showed NUGC-4 was sensitive to Lapatinib	PMC3950883
NCI-N87 cell lines	16 nM(GI50)	3 days	Evaluate the anti-proliferative effect of Lapatinib on HER2-high gastric cancer cell lines, results showed NCI-N87 was sensitive to Lapatinib	PMC3950883
A375 melanoma cells	200nM	24 h	To evaluate the inhibitory effect of Lapatinib alone or in combination with Phenformin on cell proliferation. The results showed that Lapatinib alone had a significant inhibitory effect on A375 cells, but the combination with Phenformin was more effective	PMC7252493
NT2197 cells	600 nM	24 h	To evaluate the inhibitory effect of Lapatinib alone or in combination with Phenformin on cell proliferation. The results showed that Lapatinib alone had a significant inhibitory effect on NT2197 cells, but the combination with Phenformin was more effective	PMC7252493
SkBr3	1µM	48 h	To evaluate the apoptotic response of HER2 amplified breast cancer cells to lapatinib. BIM knockdown significantly reduced lapatinib-induced apoptosis.	PMC3229203
EFM-192A	1µM	72 h	To evaluate the apoptotic response of HER2 amplified breast cancer cells to lapatinib. EFM-192A cells showed <5% apoptosis.	PMC3229203
BT-474	1µM	72 h	To evaluate the apoptotic response of HER2 amplified breast cancer cells to lapatinib. BT-474 cells showed ~65% apoptosis, while EFM-192A cells showed <5% apoptosis.	PMC3229203

NOD/scid/Il2 γ-null (NSG) mice	Breast cancer xenograft model	Oral gavage	100 mg/kg	5 days/week	To study the effect of lapatinib on HER2 blockade, results showed that lapatinib combined with other anti-HER2 therapy and anti-estrogen therapy led to rapid tumor regression to a non-palpable state.	PMC8178846
Nude mice	SGC031 PDGCX model	Oral	100 mg/kg	Twice daily for 3 weeks	Evaluate the anti-tumor efficacy of Lapatinib in MET amplification and overexpression PDGCX model, results showed Lapatinib did not significantly inhibit tumor growth	PMC3950883
NOD/SCID mice	HER2-overexpressing breast cancer model	Oral	100 mg/kg	Once daily for 3 weeks	To evaluate the efficacy of combined lapatinib and BYL719 treatment in HER2-positive breast cancer	PMC8567053
Female athymic nude mice	HER2-amplified xenograft model	Lapatinib and BKM120: oral gavage; Trastuzumab: intraperitoneal injection	100 mg/kg	Lapatinib and BKM120: daily; Trastuzumab: twice weekly; duration: 28 days	To evaluate the antitumor effects of lapatinib, trastuzumab, and BKM120 alone or in combination on HER2-amplified xenografts. Results showed that in PIK3CA wild-type tumors, the combination of lapatinib and trastuzumab induced tumor regression, and the addition of BKM120 further improved tumor regression and reduced tumor relapse after treatment discontinuation. In PIK3CA-mutant tumors, the combination of lapatinib and trastuzumab failed to induce tumor regression, while the addition of BKM120 resulted in tumor regression.	PMC3978602
Mice	MMTV-Wnt-1 mammary tumor model	Oral gavage	100 mg/kg	Twice daily for 14 days	Inhibition of tumor growth and TIC self-renewal	PMC3917843
NOD SCID mice	HT-29 colorectal tumor xenografts	Oral	60 mg/kg	Once daily for 10 days	To study the effect of lapatinib on tumor growth in HT-29 colorectal tumor xenograft model. Results showed that lapatinib combined with sorafenib significantly inhibited tumor growth, and serum phospho-CSE1L levels declined 3 days after treatment.	PMC4467675
Nude mice	NT2197 xenograft model	Phenformin via intraperitoneal injection, lapatinib via gavage	50mg/kg	Every 24 hours for 8 days	Evaluate the anti-tumor efficacy of Lapatinib and phenformin combination, showing significant inhibition of tumor growth	PMC7252493
Nude mice	HER2 amplified breast cancer xenograft model	Oral gavage	100mg/kg	Once daily for ~30 days	To evaluate the anti-tumor effect of lapatinib in HER2 amplified breast cancer xenograft models. High BIM expressing BT-474 cells were more sensitive to lapatinib, while low BIM expressing ZR7530 cells showed weaker response.	PMC3229203

{[proInfo.proName]}

CAS No.: 388082-78-8

{[proInfo.proName]}

CAS No.: 388082-78-8

Alternative Products

Product Details of Lapatinib ditosylate monohydrate

Safety of Lapatinib ditosylate monohydrate

Related Pathways of Lapatinib ditosylate monohydrate

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	1.06mL 0.21mL 0.11mL	5.30mL 1.06mL 0.53mL	10.60mL 2.12mL 1.06mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed